SynthesisWorld journal of urology2023
State of the art and future challenges of urethra-sparing stereotactic body radiotherapy for prostate cancer: a systematic review of literature.
Synthesis in World journal of urology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 2 syntheses or guidelines pooled it, 27 citations in OpenAlex.
- Reducing adverse effects in hypofractionated radiotherapy for prostate cancer: Clinical evidence and emerging mitigation strategies.Prostate cancer and prostatic diseases · 2026Pooled it
- The interplay between acute and late toxicity among patients receiving prostate radiotherapy: an individual patient data meta-analysis of six randomised trials.The Lancet. Oncology · 2025Pooled it
- Article
- Biochemical control and 2-year tolerability following stereotactic body radiotherapy for localized prostate cancer: a multicenter study in Spain.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Observational
- Dosimetric robustness of urethra sparing in ultrahypofractionated prostate SBRT using catheter-based motion tracking.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2026Article
- Impact of image-guided radiation therapy with intraprostatic seeds on long-term toxicity in prostate cancer patients undergoing risk-adapted intensification therapy.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
- A comparative assessment of deep learning and knowledge-based dose prediction models for advanced radiotherapy planning of prostate cancer with focal boosting.Physics and imaging in radiation oncology · 2026Article
- Geometric evaluation of a deep learning method for segmentation of urinary OARs on magnetic resonance imaging for prostate cancer radiotherapy.Clinical and translational radiation oncology · 2026Article
- Sharing a flexible urethral sparing SBRT prostate RapidPlan model and quantifying plan quality via dosimetric scorecard with clinical implementation.Radiation oncology (London, England) · 2025Article
- Stereotactic body radiotherapy: a second chance for radio-recurrent prostate cancer.Prostate cancer and prostatic diseases · 2025Article
- Tailoring prostate cancer external beam radiotherapy for patients with lower urinary tract symptoms.World journal of urology · 2025Review
- Enhanced urethral identification for radiotherapy planning using fat-suppressed 3D T2-weighted magnetic resonance imaging.Radiological physics and technology · 2025Article
- Urethra-sparing prostate cancer radiotherapy: Current practices and future insights from an international survey.Clinical and translational radiation oncology · 2025Article
- Associations of dose to the urethra and long-term patient-reported outcomes after radiotherapy with EBRT and HDR brachytherapy boost for prostate cancer.Clinical and translational radiation oncology · 2025Article
- Stereotactic ultrahypofractionated MR-guided radiotherapy for localized prostate cancer - Acute toxicity and patient-reported outcomes in the prospective, multicenterClinical and translational radiation oncology · 2024Article
- Developing and validating a simple urethra surrogate model to facilitate dosimetric analysis to predict genitourinary toxicity.Clinical and translational radiation oncology · 2024Article
- Stereotactic body radiation therapy for prostate cancer after surgical treatment of prostatic obstruction: Impact on urinary morbidity and mitigation strategies.Clinical and translational radiation oncology · 2024Article
- Urethra contouring on computed tomography urethrogram versus magnetic resonance imaging for stereotactic body radiotherapy in prostate cancer.Clinical and translational radiation oncology · 2024Article
- Treatment Optimization in Linac-Based SBRT for Localized Prostate Cancer: A Single-Arc versus Dual-Arc Plan Comparison.Cancers · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeDoses delivered to the urethra have been associated with an increased risk to develop long-term urinary toxicity in patients undergoing stereotactic body radiotherapy (SBRT) for prostate cancer (PCa). Aim of the present systematic review is to report on the role of urethra-sparing SBRT (US-SBRT) techniques for prostate cancer, with a focus on outcome and urinary toxicity.
methodA systematic review of the literature was performed on the PubMed database on May 2023. Based on the urethra-sparing technique, 13 studies were selected for the analysis and classified in the two following categories: "urethra-steering" SBRT (restriction of hotspots to the urethra) and "urethra dose-reduction" SBRT (dose reduction to urethra below the prescribed dose).
resultsBy limiting the urethra D
conclusionUS-SBRT techniques limiting maximum doses to urethra below a 90Gy
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.